CSF2 and central nervous system cancer: However, BLZ945 treatment decreased percentages of CD11b+Ly6G− cells in blood, while numbers of GAMs in tumors were not reduced, which was attributed to glioma-secreted factors including granulocyte-macrophage colony stimulating factor (GM-CSF) and interferon-γ supporting GAM survival.